Iwatani Y, Matsuoka K, Ode H, Kubota M, Nakata Y, Setoyama Y
mBio. 2025; 16(3):e0333224.
PMID: 39835817
PMC: 11898743.
DOI: 10.1128/mbio.03332-24.
Gaba A, Yousefi M, Bhattacharjee S, Chelico L
J Virol. 2024; 99(1):e0160624.
PMID: 39714157
PMC: 11784016.
DOI: 10.1128/jvi.01606-24.
Gao C, Ouyang W, Kutza J, Grimm T, Fields K, Lankford C
Viruses. 2023; 15(11).
PMID: 38005838
PMC: 10674259.
DOI: 10.3390/v15112160.
Hu Y, Gudnadottir R, Knecht K, Arizaga F, Jonsson S, Xiong Y
Sci Adv. 2023; 9(2):eadd3422.
PMID: 36638173
PMC: 9839330.
DOI: 10.1126/sciadv.add3422.
Barik S
Int J Mol Sci. 2022; 23(1).
PMID: 35008916
PMC: 8745392.
DOI: 10.3390/ijms23010489.
Characterization of an A3G-Vif-CRL5-CBFβ Structure Using a Cross-linking Mass Spectrometry Pipeline for Integrative Modeling of Host-Pathogen Complexes.
Kaake R, Echeverria I, Kim S, Von Dollen J, Chesarino N, Feng Y
Mol Cell Proteomics. 2021; 20:100132.
PMID: 34389466
PMC: 8459920.
DOI: 10.1016/j.mcpro.2021.100132.
Exploiting Ubiquitin Ligases for Induced Target Degradation as an Antiviral Strategy.
Verma R
Adv Exp Med Biol. 2021; 1322:339-357.
PMID: 34258747
DOI: 10.1007/978-981-16-0267-2_13.
Foamy Viruses, Bet, and APOBEC3 Restriction.
Vasudevan A, Becker D, Luedde T, Gohlke H, Munk C
Viruses. 2021; 13(3).
PMID: 33803830
PMC: 8003144.
DOI: 10.3390/v13030504.
Dual Functionality of HIV-1 Vif in APOBEC3 Counteraction and Cell Cycle Arrest.
Salamango D, Harris R
Front Microbiol. 2021; 11:622012.
PMID: 33510734
PMC: 7835321.
DOI: 10.3389/fmicb.2020.622012.
Maedi-visna virus Vif protein uses motifs distinct from HIV-1 Vif to bind zinc and the cofactor required for A3 degradation.
Knecht K, Hu Y, Rubene D, Cook M, Ziegler S, Jonsson S
J Biol Chem. 2021; 296:100045.
PMID: 33465707
PMC: 7949081.
DOI: 10.1074/jbc.RA120.015828.
Host-Viral Interactions Revealed among Shared Transcriptomics Signatures of ARDS and Thrombosis: A Clue into COVID-19 Pathogenesis.
Mishra A, Chanchal S, Ashraf M
TH Open. 2020; 4(4):e403-e412.
PMID: 33354650
PMC: 7746517.
DOI: 10.1055/s-0040-1721706.
A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
Duan S, Wang S, Song Y, Gao N, Meng L, Gai Y
J Biol Chem. 2020; 295(43):14592-14605.
PMID: 32817167
PMC: 7586213.
DOI: 10.1074/jbc.RA120.013404.
Cullin-5 Adaptor SPSB1 Controls NF-κB Activation Downstream of Multiple Signaling Pathways.
Georgana I, Maluquer de Motes C
Front Immunol. 2020; 10:3121.
PMID: 32038638
PMC: 6985365.
DOI: 10.3389/fimmu.2019.03121.
Inhibition of Vif-Mediated Degradation of APOBEC3G through Competitive Binding of Core-Binding Factor Beta.
Miyagi E, Welbourn S, Sukegawa S, Fabryova H, Kao S, Strebel K
J Virol. 2020; 94(7).
PMID: 31941780
PMC: 7081906.
DOI: 10.1128/JVI.01708-19.
Ubiquitination of Virulence Factor InlC Contributes to the Host Response to Infection.
Gouin E, Balestrino D, Rasid O, Nahori M, Villiers V, Impens F
mBio. 2019; 10(6).
PMID: 31848284
PMC: 6918085.
DOI: 10.1128/mBio.02778-19.
Cullin Ring Ubiquitin Ligases (CRLs) in Cancer: Responses to Ionizing Radiation (IR) Treatment.
Fouad S, Wells O, Hill M, DAngiolella V
Front Physiol. 2019; 10:1144.
PMID: 31632280
PMC: 6781834.
DOI: 10.3389/fphys.2019.01144.
Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.
Azimi F, Lee J
Protein Sci. 2019; 29(2):391-406.
PMID: 31518043
PMC: 6954718.
DOI: 10.1002/pro.3729.
Role of co-expressed APOBEC3F and APOBEC3G in inducing HIV-1 drug resistance.
Mohammadzadeh N, Love R, Gibson R, Arts E, Poon A, Chelico L
Heliyon. 2019; 5(4):e01498.
PMID: 31025011
PMC: 6475876.
DOI: 10.1016/j.heliyon.2019.e01498.
Natural APOBEC3C variants can elicit differential HIV-1 restriction activity.
Anderson B, Ikeda T, Moghadasi S, Martin A, Brown W, Harris R
Retrovirology. 2018; 15(1):78.
PMID: 30558640
PMC: 6297987.
DOI: 10.1186/s12977-018-0459-5.
Inhibitory Effects of HIV-2 Vpx on Replication of HIV-1.
Mahdi M, Szojka Z, Motyan J, Tozser J
J Virol. 2018; 92(14).
PMID: 29743354
PMC: 6026746.
DOI: 10.1128/JVI.00554-18.